Op den KampJAF. Lipid asymmetry in membranes. Ann Rev Biochem1979; 48: 47–71.
2.
SeigneuretMDevauxPF. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: Relation to shape changes. Proc Natl Acad Sci USA1984; 81: 3751–5.
3.
BeleznayZZachowskiADevauxPF. ATP-dependent aminophospholipid translocation in erythrocyte vesicles: Stoichiometry of transport. Biochemistry1993; 32: 3146–52.
4.
TillyRHJSendenJMGComfuriusP. Increased aminophospholipid translocase activity in human platelets during secretion. Biochim Biophys Acta1990; 1029: 188–90.
5.
BeversEMComfuriusPZwaalRFA. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta1983; 736:57–66.
6.
WilliamsonPKulickAZachowskiA. Ca2+ induces transbilayer redistribution of all major phospholipids in human erythrocytes. Biochemistry1992; 31: 6355–60.
7.
FranckPFHBeversEMLubinBH. Accelerated transbilayer movement of phosphatidylcholine in sickled erythrocytes. J Clin Invest1985; 75: 183–90.
8.
WeissHJVicicWJLagesBA. Isolated deficiency of platelet procoagulant activity. Am J Med1979; 67: 206–9.
9.
BeversEMWiedmerTComfuriusP. Defective Ca2+-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: A study of the red blood cells of Scott syndrome. Blood1992; 79: 380–8.
10.
RosingJBeversEMComfuriusP. Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood1985; 65: 1557–61.
11.
TansGRosingJThomassenMCLGD. Comparison of anticoagulant and procoagulant properties of stimulated platelets and platelet-derived microparticles. Blood1990; 77: 2641–6.
12.
SchroitAJMadsenJWTanakaY. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem1985; 260: 5131–8.
13.
FadokVALaszloDJNoblePW. Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol1993; 151: 4274–85.
14.
ExnerTTriplettD. Lupus anticoagulants: Characteristics, methods of laboratory detection and some clinical associations. In: Phospholipid Binding Antibodies. HarrisENHughesGRVAshersonRA, (eds). Boca Raton, FL, CRC Press1991: 141–58.
McNeilHPSimpsonRJChestermanCN. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120–4.
17.
MatsuuraEIgarashiYFujimotoM. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177–8.
18.
GalliMComfuriusPMaassenC. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein factor. Lancet1990; 335: 1544–7.
19.
BeversEMGalliMBarbuiT. Lupus anticoagulants IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost1991; 66: 2–5.
20.
OostingJDDerksenRHWMBobbinkIWG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism?Blood1993; 81: 2618–25.
21.
GalliMComfuriusPBarbuiT. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost1992; 68: 297–300.
22.
GalliMBarbuiTZwaalRFA. ‘Antiphospholipid antibodies’: Involvement of protein cofactors. Haematologica1993; 78: 1–4.
23.
NimpfJBeversEMBomansPHH. Prothrombinase activity of human platelets is inhibited by beta-2 glycoprotein I. Biochim Biophys Acta1986; 884: 142–9.
24.
EmlenWNieburJKaderaR. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol1994; 152: 3685–92.
25.
RoseLMLatchmanDSIsenbergDA. BCL-2 and FAS, molecules which influence apoptosis. A possible role in systemic lupus erythematosus?Autoimmunity1994; 17: 271–8.
